Emmanuel Fenouillet

Title: Emmanuel Fenouillet: Innovator in HIV Therapy

Introduction

Emmanuel Fenouillet is a notable inventor based in La Valette du Var, France. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic solutions for HIV.

Latest Patents

Fenouillet holds a patent for "Multiple branch peptide constructions for use against HIV." This invention focuses on multiple branch peptide constructions (MBPCs) that are formed from a core matrix. These MBPCs are attached to peptides derived from the V3 loop of the envelope glycoprotein of HIV-1. The patent emphasizes the amino acid sequence GPGR (SEQ ID NO: 5), preferably in the form GPGRAF, while ensuring that the peptides are free of certain sequences that could hinder their effectiveness. The MBPCs are designed to prevent virus/cell infection and cell-to-cell virus transmission between CD4+ cells and HIV, without compromising the immunogenic role of these cells. Additionally, they are effective in blocking CD4 receptors on lymphocytes and macrophages, as well as GalCer receptors on colon epithelial cells. Importantly, these MBPCs are non-immunogenic and non-toxic at therapeutic doses, making them suitable for clinical use.

Career Highlights

Emmanuel Fenouillet is associated with Armel S.A., where he continues to advance his research and innovations. His work has garnered attention for its potential impact on HIV treatment and prevention.

Collaborations

Fenouillet has collaborated with notable colleagues, including Jean M Sabatier and Abdelaziz Benjouad. Their combined expertise contributes to the ongoing research and development in the field of HIV therapies.

Conclusion

Emmanuel Fenouillet's innovative work in developing peptide constructions for HIV therapy showcases his commitment to advancing medical science. His contributions are vital in the fight against HIV, offering hope for effective treatments in the future.